State of the art: medical treatment of Peyronie's disease

Bibliography

• Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350-3
   PubMed Web of Science ®Google Scholar
• Larsen SM, Levine LA. Review of non-surgical treatment options for Peyronie's disease. Int J Impot Res 2012;24:1-10
   PubMed Web of Science ®Google Scholar
• Gholami SS, Lue TF. Peyronie's disease. Urol Clin North Am 2001;28:377-90
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9
   PubMed Web of Science ®Google Scholar
• Deveci S, Hopps CV, O'Brien K, et al. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007;4:485-90
   PubMed Web of Science ®Google Scholar
• Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflamm Allergy Drug Targets 2012;11:48-57
   PubMedGoogle Scholar
• Smith BH. Subclinical Peyronie's disease. Am J Clin Pathol 1969;52:385-90
   PubMed Web of Science ®Google Scholar
• Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991;25:89-94
   PubMed Web of Science ®Google Scholar
• Gur S, Kadowitz PJ, Hellstrom WJ. Drugs of the future for Peyronie's disease. Med Hypotheses 2012;78:305-11
   PubMed Web of Science ®Google Scholar
• Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie's disease. J Sex Med 2008;5:1985-90
   PubMed Web of Science ®Google Scholar
• Segal RL, Burnett AL. Surgical Management for Peyronie's Disease. World J Men's Health 2013;31:1-11
   PubMedGoogle Scholar
• Trost LW, Gur S, Hellstrom WJ. Pharmacological Management of Peyronie's Disease. Drugs 2007;67:527-45
   PubMed Web of Science ®Google Scholar
• Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948;41:173-7
   PubMedGoogle Scholar
• Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007;178:1398-403; discussion 403
   PubMed Web of Science ®Google Scholar
• Smith JF, Walsh TJ, Lue TF. Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res 2008;20:445-59
   PubMed Web of Science ®Google Scholar
• Halal AA, Geavlete P, Ceban E. Pharmacological therapy in patients diagnosed with Peyronie's disease. J Med Life 2012;5:192-5
   PubMedGoogle Scholar
• El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al. The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999;161:1980-3
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000;12:169-75
   PubMed Web of Science ®Google Scholar
• Lin G, Shindel AW, Banie L, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010;7:1787-97
   PubMed Web of Science ®Google Scholar
• Fda. FDA approval letter Pentoxifylline. 1998
   Google Scholar
• Astorga R, Cantero O, Contreras D, et al. Intralesional recombinant interferon alpha-2b in Peyronie's disease. Arch Esp Urol 2000;53:665-71
   PubMedGoogle Scholar
• Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl 2011;13:322-5
   PubMed Web of Science ®Google Scholar
• Weidner W, Hauck EW, Schnitker J; Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-5; discussion 5-6
   PubMed Web of Science ®Google Scholar
• Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001;88:63-7
   PubMed Web of Science ®Google Scholar
• Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Kovanecz I, Nolazco G, et al. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006;97:625-33
   PubMed Web of Science ®Google Scholar
• Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 2011;8:1472-7
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol 2012;62:543-52
   PubMed Web of Science ®Google Scholar
• Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002;168:2483-5
   PubMed Web of Science ®Google Scholar
• Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C. Iontophoresis in the conservative treatment of Peyronie's disease: preliminary experience. Arch Ital Urol Androl 1997;69:323-7
   PubMedGoogle Scholar
• Cabello Benavente R, Moncada Iribarren I, de Palacio Espana A, et al Transdermal iontophoresis with dexamethasone and verapamil for Peyronie's disease. Actas Urol Esp 2005;29:955-60
   PubMedGoogle Scholar
• Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003;169:1775-8
   PubMed Web of Science ®Google Scholar
• Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J Urol 2007;177:972-5
   PubMed Web of Science ®Google Scholar
• Riedl CR, Sternig P, Galle G, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005;48:656-61
   PubMed Web of Science ®Google Scholar
• Berlin T. Orgotein versus hydrocortisone in the treatment of Peyronie's disease. A randomized study. J Urol 1986;135(Suppl):103A-392A
   Google Scholar
• Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998;51:620-6
   PubMed Web of Science ®Google Scholar
• Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002;89:895-900
   PubMed Web of Science ®Google Scholar
• Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007;69:950-4
   PubMed Web of Science ®Google Scholar
• Chung E, Garcia F, Young LD, et al. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol 2013;189:380-4
   PubMed Web of Science ®Google Scholar
• Lacy GL II, Adams DM, Hellstrom WJ. Intralesional interferon-alpha-2b for the treatment of Peyronie's disease. Int J Impot Res 2002;14:336-9
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8
   PubMed Web of Science ®Google Scholar
• Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol 1990;95:75S-80S
   PubMed Web of Science ®Google Scholar
• Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha 2b. Eur Urol 1995;28:236-40
   PubMed Web of Science ®Google Scholar
• Ahuja S, Bivalacqua TJ, Case J, et al. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999;20:444-8
   PubMedGoogle Scholar
• Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int 2001;87:654-7
   PubMed Web of Science ®Google Scholar
• Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997;79:40-2
   PubMedGoogle Scholar
• Polat O, Gul O, Ozbey I, et al. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol 1997;29:465-71
   PubMedGoogle Scholar
• Dang G, Matern R, Bivalacqua TJ, et al. Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease. South Med J 2004;97:42-6
   PubMed Web of Science ®Google Scholar
• Kendirci M, Usta MF, Matern RV, et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005;2:709-15
   PubMed Web of Science ®Google Scholar
• Inal T, Tokatli Z, Akand M, et al. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006;67:1038-42
   PubMed Web of Science ®Google Scholar
• Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety, and tolerability of collagenase clostridium histolyticum in the treatment of Peyronie's disease from 2 large double-blind, randomized, placebo-controlled phase 3 studies. J Urol 2013;190(1):199-207
   PubMed Web of Science ®Google Scholar
• Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 2012;187:2268-74
   PubMed Web of Science ®Google Scholar
• Van Wart HE, Steinbrink DR. Complementary substrate specificities of class I and class II collagenases from Clostridium histolyticum. Biochemistry 1985;24:6520-6
   PubMed Web of Science ®Google Scholar
• Gilpin D, Coleman S, Hall S, et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010;35:2027-38.e1
   PubMed Web of Science ®Google Scholar
• Xiaflex Package Insert: Manufactured and distributed by: Auxilium Pharmaceuticals, Inc. Malvern, PA 19355 USA. This Medication Guide has been approved by the U.S. Food and Drug Administration. US License No. 1816 US Patent No. 7,811,560 PL-1109-001.c. 2012. Available from: https://www.xiaflex.com/_assets/pdf/PL-1109-001.c_pi_medguide_combo.pdf
   Google Scholar
• ClinicalTrials.gov. Pharmacokinetics of a single treatment cycle of AA4500 0.58 mg in men with Peyronie's disease
   Google Scholar
• Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982;10:135-40
   PubMed Web of Science ®Google Scholar
• Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg Am 2000;25:629-36
   PubMed Web of Science ®Google Scholar
• Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1(1):6-23
   PubMed Web of Science ®Google Scholar
• Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7(11):3572-88
   PubMed Web of Science ®Google Scholar